Abstract Carcinoembryonic antigen (CEA) is still the only routinely used biomarker in colorectal cancer (CRC), but its utility is hampered by poor specificity and sensitivity, and the search for novel biomarkers is highly warranted. The nonspecific cross-reacting antigen 2 (NCA-2), a truncated CEA species molecule which is transcribed from the same gene, has been suggested as an alternative biomarker to CEA. In the present work, specific immunofluorometric assays were used for detection of NCA-2 and full-length CEA in bone marrow plasma from 277 CRC patients to assess their value as prognostic biomarkers, and detection was also performed in tumor tissue and a CRC cell line. Elevated plasma CEA was associated with advanced tumor stage at diagnosis and adverse patient outcome, while for NCA-2, although the same trends were observed, no additional prognostic information was gained. While specific detection of NCA-2 was clearly achieved in plasma samples, cross-reactivity with full-length CEA was observed when the antigen was exposed to common fixation chemicals. The results from this study indicate that NCA-2 is probably not a prognostic biomarker in CRC and, furthermore, underline the issue of antibody specificity when investigating CEA species molecules.
Introduction
Carcinoembryonic antigen (CEA) was one of the first biomarkers to be described and is still measured in serum for diagnosis and monitoring of colorectal cancer (CRC). This highly glycosylated 180-kDa protein is released into the blood stream by unknown mechanisms to generate elevated levels detectable in serum or plasma of patients with CRC. In particular, serial measurements of CEA may be useful, with the potential to detect disease recurrence with sensitivity and specificity of up to 80% and 70%, respectively [1] [2] [3] [4] [5] [6] . In addition, high CEA concentrations have been shown to be a predictor of poor outcome in CRC [5] . However, specificity is limited by elevated CEA levels in smokers, in benign diseases (perforated ulcer and liver disease) as well as in patients with epithelial tumors of non-intestinal origin [7, 8] . Conversely, sensitivity is affected by heterogeneous CEA tumor expression, as for instance some poorly differentiated tumors may not express CEA [9] [10] [11] . In attempts to improve sensitivity, serum CEA has been examined together with other plasma proteins, such as TIMP-1, osteopontin, CA 19-9, and cathepsin B, but none of the additional markers have added clear advantages to using CEA alone [12] [13] [14] , and the search for reliable diagnostic and prognostic biomarkers is still warranted in CRC.
The CEA gene family, comprised of 28 expressed genes/ pseudogenes, is divided into two branches: CEACAM and PSG (pregnancy-specific glycoprotein) [15] . The CEACAM is further divided into subclasses: CEACAM 1, 3, 4 which are generally anchored to the cell surface by cytoplasmic domains and CEACAM 5-8 which are anchored through glycophosphatidylinositol lipid moieties. As antibody-based assays for detecting CEA were established by several groups, it became evident that the presence of several cross-reacting antigens led to discrepancies between the results when using different antibodies [16] . The discovery of one such molecule, the nonspecific cross-reacting antigen 2 (NCA-2, a truncated version of CEACAM5), a 160-kDa protein transcribed from the CEA gene which was first isolated from meconium in 1973 [17] , was followed by several studies examining the cross-reactivity of CEA antibodies [16, 18, 19] . NCA-2 in serum has been proposed to be an alternative biomarker to CEA [3] , but this has not been examined in large clinical panels. We previously established single chain Fv-based immunofluorometric assays for detecting NCA-2, full-length CEA (CEA spec ), and a broad range of CEA species molecules (CEA total ) [20] . In a small clinical series (64 cancer patients), NCA-2 was found to be present in serum samples, and the values were shown to account for the discrepancy between measured CEA spec and CEA total . The present work was undertaken to validate these initial findings in a more comprehensive cohort of CRC patients and also assess the value of NCA-2 as a prognostic biomarker in CRC.
Materials and methods

Patients and clinical samples
Three hundred sixteen patients were prospectively included in the study at the time of primary surgery for assumed or verified CRC. Patients were recruited from five hospitals in the Oslo region, between the year 1998 and 2000 [21] . The study was approved by the Regional Ethics Committee (Health Region II, Norway) and informed consent was obtained from the patients. Thirty-one patients were excluded from statistical analysis for the following reasons: not invasive cancer (25) , histology other than adenocarcinoma (5), and unknown stage of disease (1) . In addition, sections were not obtainable in eight cases. At surgery, a total average of 20 ml of bone marrow was drawn from both anterior iliac crests, and following separation of mononuclear cells (MNC) by gradient centrifugation using CPT tubes (Becton Dickinson Co., Franklin Lakes, NJ, USA), plasma was collected and stored at −20°C. Bone marrow plasma was unavailable in four cases, and for technical reasons, analysis of individual proteins was not possible in some cases leaving 271 and 266 cases for bone marrow plasma CEA and NCA-2 analysis, respectively. Preoperative CEA serum values were available for 152 patients. Following surgery, resected specimens were processed routinely for histopathological assessment and additional tumor tissue was sampled and snap-frozen in liquid nitrogen. To ensure consistent staging and grading, a reference pathologist reevaluated all primary sections, and representative samples for each tumor were identified for subsequent immunohistochemical analysis. Follow-up data were obtained from the participating hospitals and from the general practitioners (for the patients not attending scheduled controls). Metastasis was verified by radiological examination. Survival data were obtained from the National Registry of Norway and updated by October 1, 2008 with the cause of death registered and classified as death from colorectal cancer, death of other causes, or death of unknown causes. For overall survival, median follow-up of patients still alive was 9.1 years (range 8.2-10.0). For comparison of NCA-2 in serum and bone marrow plasma, 20 corresponding bone marrow plasma and peripheral blood serum samples were collected from patients with locally advanced rectal cancer [22] .
CEA and NCA-2 antibodies and protein preparations Anti-CEA total (12-140-10), 12-140-1, and anti-NCA-2 (O-22) are in-house-produced monoclonal antibodies [23] . Anti-CEA (12-140-1) was used as a tracer in immunofluorometric assay (IFMA). Monoclonal antibody O-22 was obtained from a fusion with the same spleen used for generating the scFv phage library. Selection and specificity of the Mab was performed in a similar way as described for the scFv for NCA-2 [20, 24] . Anti-CEA total recognizes an epitope present in full-length CEA and the truncated NCA-2 version and is used as the solid-phase antibody in the IFMA [25] . Anti-CEA spec (T84.66) was obtained from hybridoma cell lines purchased from ATCC (Manassas, VA, USA), and this antibody apparently binds to an epitope not present in NCA-2 and is thus regarded to be full-length CEA specific. All primary antibodies used were mouse monoclonal antibodies. NCA-2 was purified from a pool of meconium from infants born at term and extracted with perchloric acid extraction followed by immunoaffinity chromatography with the anti-CEA monoclonal antibody 12-140-2 as previously described [20] . Recombinant human CEA (rhCEA) was obtained from R&D Systems (Minneapolis, USA).
Immunofluorometric assays
Determinations of total CEA, specific CEA, and NCA-2 were performed by time-resolved immunofluorometric assays. For all three assays, the solid-phase antibodies were biotinylated (Fab′) 2 fragments, and Eu 3+ -labeled monoclonal antibodies were used for detection. The monoclonal antibody pairs were for total CEA assay, 12-140-10 and 12-140-1, for specific-CEA, T84.66 and 12-140-1, and for NCA-2, 12-140-10 and O-22. Calibrators were the same in the two CEA assays [16] , while calibrators for NCA-2 were dilutions of the antigen purified from meconium, as previously described [20] . For assaying samples, 0.4 μg/well of biotinylated (Fab′) 2 in 150 μl Delfia assay buffer (0.05 M Tris-HCl, 0.05 M NaCl, 0.02 M diethylene triamine penta acetic acid, 0.5 g/l NaN 3 , 0.1 ml/l Tween 20, 20 mg/l Amaranth, 0.5 g/l BSA, 0.5 g/l bovine IgG, and 15 mg/l MAK33-IgG (Roche Molecular Biochemicals), pH 7.8) was incubated under continuous shaking for 30 min before washing three times with Delfia wash solution (0.05 M Tris-HCl, 0.15 M NaCl, 0.05% Tween 20, 0.1% Germall, pH 7.8). Twenty-five microliters of calibrator or sample and 100 μl assay buffer were then added to duplicate wells, followed by continuous shaking for 60 min. Following three washes, 200 μl/well Eu 3+ -labeled antibody was added and plates incubated for another 60 min of continuous shaking. After six washes, 200 μl/well of Delfia enhancement solution (Perkin-Elmer Life Science/Wallac Oy) was added, followed by incubation with shaking at room temperature for 5 min. Fluorescence was measured in a time-resolved fluorometer. The assays were performed either manually or automated using an AutoDELFIA instrument (Perkin Elmer Life and Analytical Sciences/Wallac Oy).
The analytical detection limit for total CEA assay was 0.2 μg/l and total imprecision (mean CV) at 5.2 and 25.9 μg/l of 5% and 3%, respectively. The analytical detection limit for specific CEA assay was 0.2 μg/l and total imprecision at 3.2 and 14.3 μg/l of 9% and 6%, respectively, while the corresponding values for NCA-2 assay were 1.2 μg/l in detection limit and mean CV at 2.5 and 14.9 μg/l of 16% and 5%, respectively.
For the experiments analyzing the effects of fixation chemicals on cross-reactivity of the anti-NCA-2, rhCEA was mixed with 40 μl of either PBS (Bio Whittaker, Verviers, Belgium), SDS (NuPage, LDS sample buffer, Invitrogen, San Diego, CA, USA), formalin (10% SigmaAldrich), or methanol (WVR) before diluting it 1:100 and analyzed by IFMA.
Immunohistochemistry
Three-micrometer sections were prepared from formalinfixed, paraffin-embedded tumor samples and immunostained using the Dako EnVision ™ + System, peroxidase (3,3′-diaminobenzidine) (K4007, Dako A/S, Glostrup, Denmark), and Dako Autostainer. Sections were deparaffinized and microwaved in 10 mM citrate buffer, pH 6.0 to unmask the epitopes and treated with 0.03% hydrogen peroxide (H 2 O 2 ) for 5 min to block endogenous peroxidase and then sequentially incubated with monoclonal antibodies CEA spec (T84.66, 1.6 μg/ml) or NCA-2 (O-22, 0.6 μg/ml) for 30 min at room temperature and peroxidase-labeled polymer conjugated to goat anti-mouse for 30 min. The tissue was stained for 10 min with 3,3′-diaminobenzidine tetrahydrochloride and counterstained with hematoxylin, dehydrated, and mounted in Diatex. Negative controls included substitution of the monoclonal antibody with mouse myeloma protein of the same subclass and concentration as the monoclonal antibody. All negative controls revealed no staining. Immunostaining was scored with respect to the percentage of positive tumor cells (1, <10%; 2, 10-50%; 3, >50%) and intensity of staining (1, weak/ absent; 2, moderate; 3, strong). The scoring results of extent and intensity were multiplied to give a composite score (1, 2, 3, 4, 6, and 9) for each tumor. For statistical analysis, tumors with scores 1-6 were grouped as low level and 9 as high level.
Cell culture
The colorectal carcinoma cell line WiDr was purchased from ATCC and cultivated in RPMI-1640 (Bio Whittaker) supplemented with 10% fetal bovine serum (PAA Laboratories, Pashing, Austria), 1 mM HEPES, and 2 mM glutamine (Invitrogen). The cell line was negative for mycoplasma infection (Venor GeM Mycoplasma Detection kit for conventional PCR, Minerva Biolabs, Berlin, Germany).
Western immunoblot analysis
Protein lysates were prepared by suspending tumor tissue or WiDr cell pellets in lysis buffer (150 mM NaCl, 50 mM Tris pH 7.5, 0.1% NP-40, 1 mM phenylmethanesulfonyl fluoride, and 0.01 μg/μl each of leupeptin, aprotinin, and pepstatin), followed by sonication and centrifugation at 13,000×g for 10 min. NuPAGE LDS sample buffer (4×) (Invitrogen) and NuPAGE sample reducing agent (10×) (Invitrogen) were added to 30 μg total protein lysate from WiDr cells or tumor tissue and heated at 70°C for 10 min before the samples were separated by 4-12% gradient SDS polyacrylamide gel electrophoresis (Novex NuPage, Invitrogen) with the NuPage MES buffer according to the manufacturer's instructions (Invitrogen). The proteins were thereafter transferred onto Immobilon-P membranes (Millipore, Bedford, MA, USA). The membranes were blocked in 10% nonfat dry milk in TBST (10% 5 M NaCl, 0.25% Tween, and 2% Tris pH 7.5) for 60 min and then incubated with primary monoclonal antibodies at room temperature for 60 min at the following end concentrations: anti-α-tubulin (0.2 μg/ml; Oncogene Research Products), anti-CEA total (2.4 μg/ml), anti-CEA spec (4.2 μg/ml), and anti-NCA-2 (2.4 μg/ml). After washing with TBST, blots were incubated with rabbit antimouse secondary antibody (Dako) for 60 min at room temperature, and the bands were visualized using ECL chemiluminescence substrate (Amersham Pharmacia Biotech, Buckinghamshire, UK) and developed on an AGFA CURIX 60 machine using Kodac Medical X-ray film.
Confocal microscopy
WiDr cells were seeded on to glass cover slips in 24-well plates (120,000 per well) and left overnight in growth medium at 37°C. The cells were washed in PBS (Bio Whittaker) and fixed with 500 μl formalin (10%) or methanol for 20 min, thereafter blocked in PBS with 0.1% TR-X-100, 1× BSA. The cover slips were incubated in a total volume of 100 μl blocking buffer (PBS with 0.1% TR-X-100, 1× BSA) with primary antibodies anti-CEA spec , anti-NCA-2, and rat anti-human CD49f (anti-α-6-integrin, BD Pharmingen, San Diego, CA, USA) at final concentrations of 8.6, 9.6, and 10 μg/ml, respectively, for 60 min at room temperature, followed by 3× washing with PBS and thereafter incubation with secondary antibodies antimouse Alexa-488 (Cy2, Invitrogen) and anti-rat Alexa 568 (Cy3, Invitrogen) according to the manufacturer's instructions for 30 min at room temperature. After washing with PBS, the cover slips were fixed with Pro Long Gold with DAPI (Invitrogen) on to a glass slide. Four-micrometer tissue sections from a tumor sample were prepared similar to the WiDr cells described above. 
Statistical analyses
Associations between preoperative serum and bone marrow plasma CEA and NCA-2 and between bone marrow plasma NCA-2 values and the difference (CEA total -CEA spec ) were studied by linear regression analysis. For analyzing associations between plasma CEA total , CEA spec , and NCA-2 and clinicopathological variables and outcome, data were arranged dichotomously into high and low values. For CEA total and CEA spec , the normal distribution in a healthy population is well described, and cut-off values of 5 μg/l were used [1] . Since normal plasma levels of NCA-2 are unknown, a range of cut-off values were explored, and for the analyses presented in Table 1 and Fig. 2, 2 μg/l was used.
Associations with clinicopathological variables were tested using two-tailed Fisher's exact test or linear-by-linear association chi-square test. Survival was estimated using the Kaplan-Meier method and compared using the log-rank test. Overall and metastasis-free survival was calculated from date of surgery until the date of death or diagnosis of metastasis. All statistical analyses were performed using SPSS version 16.0 (SPSS Inc., Chicago, MO, USA) and p values<0.05 were considered to be statistically significant.
Results
CEA and NCA-2 in bone marrow plasma
The suitability of bone marrow plasma for detection of CEA and NCA-2 was assessed by comparing preoperative serum measurements of CEA total and NCA-2 with corresponding results obtained in bone marrow plasma. Results were found to correlate well (CEA linear R 2 =0.838, p<0.001 and NCA-2 linear R 2 =0.912, p<0.01), suggesting that both CEA and NCA-2 can be reliably detected in bone marrow plasma (Fig. 1a, b) . Median values (range) in bone marrow plasma were as follows: CEA total , 2.5 μg/l (0-3,023.2 μg/l); CEA spec , 2.0 μg/l (0-3,143.6 μg/l); and NCA-2, 0.8 μg/l (0-714.4 μg/l). Since previous studies have suggested a quantitative association between measured CEA total , CEA spec , and NCA-2, the relationship between these CEA variants was examined in this panel [20] . When examining the correlation between figures generated by subtracting values for CEA spec from CEA total and the measured value for NCA-2 in plasma samples, a strong correlation was detected (linear R 2 =0.928, p<0.001) (Fig. 1c) .
Associations between plasma CEA and NCA-2 and clinicopathological parameters Associations between plasma CEA total , CEA spec , and NCA-2 and clinicopathological parameters of the study cohort of 277 patients were then studied. Since the results for CEA spec and CEA total were very similar and CEA total is the analysis used in the clinic, detailed results are presented for CEA total and NCA-2 (Table 1) . High levels of CEA total (>5 μg/l) and NCA-2 (>2 μg/l) were associated with advanced tumor stage (p≤0.01), with both pT stage and pN stage contributing to the association (p ≤ 0.01). High concentrations of CEA total were associated with decreased lymphocyte infiltration (p=0.04), while high NCA-2 concentrations showed association with increased vascular invasion (p=0.03). High levels of NCA-2 and CEA spec were associated with perineural invasion (p≤0.01 and p= 0.03) while CEA total was not (p=0.12).
Associations between plasma CEA and NCA-2 and patient outcome
The presence of elevated CEA total plasma concentrations was associated with poor overall survival (p=0.003) and metastasis-free survival (p=0.006) (Fig. 2a, b) . Patients with high concentrations of CEA total had a 5-year overall survival rate of 53% compared to 77% for patients with low CEA concentrations. Similarly, high concentrations of NCA-2 were associated with poor overall survival (p= 0.021), while no statistically significant association was found for metastasis-free survival (p=0.11) (Fig. 2c, d ). The 5-year survival rate for patients with high concentrations of NCA-2 was 60% compared to 75% with low concentrations. For disease-specific survival, the differences between NCA-2 high and low groups did not reach statistical significance (p=0.26), while the associations for CEA were similar to the other end points (p=0.001, data not shown).
Immunohistochemistry
Immunohistochemical analysis performed on the tumor panel with the anti-CEA spec antibody revealed, as would be expected from previous immunohistochemical studies [26] , that CEA was highly expressed by tumor cells with respect to staining intensity and fraction of CEA expressing cells, and both diffuse cytoplasmic and membranous stainings were observed (Fig. 3a) . Because CEA was expressed in a majority of the tumor tissues analyzed, the very low expressing category (CEA composite score<6) amounted to only 13 patients. We therefore divided CEA composite scores into high/low categories with a low expression category comprising composite scores 0-6, containing 87 patients (31%), and a high expression category with scores >6, with 190 patients (69%). High CEA expression was associated with the presence of tumor lymphocyte infiltration (p=0.03) (data not shown), but otherwise no associations were observed between expression levels and clinicopathological data or with outcome parameters. Surprisingly, almost the same intensity and staining distribution was observed for NCA-2, and dividing the composite scores into the same high/low level as CEA gave a distribution of 0-6=75 (27%) and >6=202 (73%).
IFMA and western blot analyses of protein lysates and rhCEA and NCA-2
The apparent incongruity observed between low plasma levels and high tissue expression of NCA-2 in the clinical samples warranted additional investigations, and western (n=152) were plotted against the results obtained in bone marrow plasma, and upon fitting a linear regression line, good correlation between the two measurements was observed. b Preoperative serum NCA-2 values were plotted against the results obtained in bone marrow plasma samples from 20 patients with locally advanced rectal cancer, and good correlation between the measurements was observed. c Plasma values obtained for NCA-2 were plotted against the difference (CEA total − CEA spec ), and the high degree of correspondence indicated that NCA-2 accounts for a substantial portion of the observed discrepancy between CEA total and CEA spec blot and IFMA analyses were performed on protein lysates from tumor samples, the CRC cell line WiDr, purified NCA-2, and rhCEA. By western blot analysis, anti-CEA total detected both CEA variants, with a band corresponding to full-length CEA at approximately 180 kDa, and NCA-2 was detected as a band appearing distinctly lower in the gel, as would be expected from its slightly smaller molecular size (160 kDa) (Fig. 4a) . Anti-CEA spec detected only fulllength CEA, whereas surprisingly, anti-NCA-2 detected not only NCA-2 but also rhCEA. In the tumor and WiDr protein lysates, bands corresponding to full-length CEA were detected with all three antibodies, confirming the apparent cross-reactivity with full-length CEA under these conditions. In the lysates, no NCA-2 bands were observed, suggesting that NCA-2 levels were very low in the tumor and cell line samples, at least below the detection limit for western blot analysis. By IFMA, low levels of NCA-2 could be detected in the lysates, representing a small fraction of total CEA present in the lysates and corresponding more closely with what would be expected based on the plasma results (Fig. 4b) .
Immunofluorescence staining and confocal microscopy Suspecting that sample handling might influence antibody specificity, immunofluorescence staining with anti-CEA spec and anti-NCA-2 was performed on WiDr cells and a tumor sample using different fixation strategies (methanol and formalin) (Fig. 3b, c) . CEA was detected as membranebound, colocalizing with α-6-integrin (which is a commonly used cell surface marker), as well as diffusely located in tumor cell cytoplasm, which is in agreement with the immunohistochemistry results. A similar expression pattern was observed upon staining with the anti-NCA-2 antibody, regardless of the fixation method. Since NCA-2 levels were very low in both the tumor sample and the cell line (by IFMA), we now suspected that cross-reactivity could represent a problem, not only for western blot analysis, but also with other analytical strategies in which the native conformation of CEA might have been compromised.
IFMA of recombinant CEA under denaturing conditions
To assess whether CEA might be modified to induce crossreactivity, rhCEA was pretreated with PBS, SDS, methanol, or formalin and then analyzed using the NCA-2 IFMA. All the denaturing treatments resulted in increased reactivity, a finding that was most pronounced upon exposure to SDS, which resulted in a three-to fivefold increase in measured signal intensity (Fig. 4c) .
Discussion
In this work, the presence of CEA and NCA-2 was analyzed in bone marrow plasma and tumor tissue from CRC patients, and associations with clinicopathological data and patient outcome were explored. Plasma concentrations of CEA total , CEA spec , and NCA-2 were in accordance with the results from a previous study using the same IFMAs [20] . High levels of CEA and NCA-2 were associated with advanced tumor stage at diagnosis, and elevated plasma CEA (>5 μg/l) was associated with poor overall, disease-free, and metastasis-free survival. Interestingly, our results for CEA in bone marrow plasma were quantitatively very similar to preoperative serum measurements, and the associations found with patient outcome were in accordance with previous studies [27] [28] [29] [30] , suggesting that bone marrow plasma was a relevant sample material. To our knowledge, the presence of NCA-2 has not previously been examined in a comprehensive cohort of CRC patients, nor has its utility as a prognostic biomarker been assessed, as studies of NCA-2 have focused mainly on the CEA cross-reactivity issue [16, 18, 20, 31, 32] . When exploring associations between plasma NCA-2 and patient outcome, the same trends that were observed for plasma CEA were found. High NCA-2 (>2 μg/l) was associated with poor overall survival, whereas the differences between high and low NCA-2 values observed for metastasis-free and disease-free survival were not statistically significant. Based on the present results, the associations between plasma NCA-2 levels and clinical outcome were weaker than for CEA, although exhibiting the same trends, and NCA-2 does not seem to contribute additional prognostic information in CRC. As a biomarker, CEA has most commonly been examined in serum, but immunohistochemical staining of tumor tissue with anti-CEA is routinely used as a marker of intestinal tumor origin, and tumor CEA has by some investigators been suggested as a prognostic biomarker [33] . When our tumor panel was immunostained with anti-CEA spec , a generally high expression of CEA was observed, and expression levels were not associated with patient outcome. Surprisingly, when tumor samples were stained with anti-NCA-2, a similar high expression was detected with respect to both signal intensity and distribution compared to CEA. These results were in contrast to the very low levels of NCA-2 detected in plasma relative to CEA, a finding that suggested the possibility of antibody cross-reactivity and instigated further experiments to elucidate this issue.
The subject of CEA antibody specificity and crossreactivity with other antigens like NCA (CEACAM6) and NCA-2 has previously been extensively examined [31, 34, 35] , and antibodies that recognize only full-length CEA are commercially available. The presence of NCA-2 has, however, mostly been studied as a cross-reacting molecule in CEA detection assays and not for its own merit, and thus, little is known about the specificity of NCA-2 antibodies in different experimental settings. The surprisingly high tissue reactivity with the anti-NCA-2 antibody was in clear contrast to the relatively low concentrations detected in plasma, and when tissue samples and cell line lysates were examined together with purified NCA-2 and rhCEA by western blot analysis, no bands corresponding to NCA-2 were detected in the tissue lysates, whereas distinct bands were detected corresponding to full-length CEA. The anti-CEA spec antibody clearly did not cross-react with NCA-2, while anti-CEA total recognized both antigens, as expected. These results suggested a possible cross-reactivity between the NCA-2 antibody and full-length CEA and led us to question whether the observed staining in tumor tissue could in fact be caused by the same phenomenon. Since anti-NCA-2 did not recognize full-length CEA in its native form when analyzed by IFMA, we considered the possibility that the anti-NCA-2 epitope might be prone to conformational changes depending on chemical modifications that could be caused by sample processing prior to analysis. To further clarify this issue, tumor tissue and WiDr cells were exposed to different fixation strategies (formalin and methanol) prior to immunofluorescence staining and confocal microscopy analysis, and both strategies resulted in almost identical staining with anti-NCA-2 and anti-CEA spec antibodies, essentially corroborating the results from immunohistochemistry and western blots. Finally, rhCEA was exposed to the different chemicals (PBS, formalin, methanol, and SDS) and probed with anti-NCA-2 by IFMA. All fixation strategies resulted in increased reactivity in the NCA-2 IFMA, suggesting that the NCA-2 epitope probably is present in full-length CEA, that it is masked when the molecule is in its native form, and that it becomes available for antibody binding and may contribute to false detection of NCA-2 when the sample is subjected to these common fixation chemicals [36, 37] .
The proposed binding site for anti-CEA total is in the Nterminal part of the molecule, which explains that it also recognizes NCA-2, which shares this part of the amino acid sequence with CEA [38] . The epitope for anti-CEA spec is at the C-terminus of full-length CEA, and since this part of the molecule is absent in NCA-2, no cross-reactivity would be expected [25] . For anti-NCA-2, the exact position and molecular composition of the epitope is unknown, but it is thought to be located in the C-terminal part of NCA-2. Since most antibodies, including the CEA and NCA-2 antibodies used in this work, are produced from native proteins or peptides, modification of epitopes by chemical agents may influence antibody reactivity in different ways [37, 39, 40] . Furthermore, NCA-2 and CEA have different glycosylation patterns, and for many glycoproteins, the carbohydrate groups confer important properties such as conformational stability and protease resistance [41, 42] . The CEA sugar chains may consequently contribute to mask epitopes recognized by anti-NCA-2, and exposure to chemical agents could reveal these epitopes to allow detection. Thus, the conditions imposed on the CEA antigen in these studies might evoke conformational changes that could explain the apparent cross-reactivity associated with the non-native state.
NCA-2 seems to constitute a relatively constant fraction of CEA species molecules in human plasma (and serum), and in this study, the presence of CEA and NCA-2 was analyzed in a cohort of CRC patients to evaluate its merit as a prognostic biomarker. Elevated plasma CEA was associated with adverse patient outcome, and although NCA-2 exhibited the same associative trends, no additional prognostic information was gained. Although the IFMA analysis of plasma samples left no doubt as to its specific detection of NCA-2, cross-reactivity with full-length CEA was apparent when the antigen was exposed to common fixation chemicals. In conclusion, the results from this study indicate that NCA-2 is probably not a prognostic biomarker in CRC. Our results also reemphasize the question of antibody specificity and suggest increased awareness regarding detection of different CEA species molecules, particularly under conditions deviating from the native state.
